Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01126099 · ClinicalTrials.gov registry record · NA
Prazosin Treatment for Disruptive Agitation in Alzheimer's Disease
A NA study, sponsored by Seattle Institute for Biomedical and Clinical Research.
- Completed
- Registry status
- NA
- Development phase
- 20
- Enrollment target
NCT01126099 is a NA study that has completed, run by Seattle Institute for Biomedical and Clinical Research. The registered enrollment target is 20 participants.
The verdict
NCT01126099, a NA study, has completed, sponsored by Seattle Institute for Biomedical and Clinical Research.
- COMPLETED
- Registry status
- NA
- Development phase
- 20 participants
- Enrollment target
Study Summary
A study of outpatient participants with Alzheimer's disease or a related dementia who have difficult behaviors that are upsetting for them or their caregivers. Prazosin is a medication that is commonly used to treat people with high blood pressure. Research with prazosin has shown that it may be effective in treating behavioral problems by reducing excess adrenalin effects in the brain.
Interventions
- DRUG Placebo
- DRUG Prazosin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2010-03 |
| Est. Completion | 2014-03 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01126099
The ClinicalTrials.gov registry entry for NCT01126099 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Seattle Institute for Biomedical and Clinical Research, which has 43 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT01126099 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01126099 about?
NCT01126099 is a clinical study titled "Prazosin Treatment for Disruptive Agitation in Alzheimer's Disease". A study of outpatient participants with Alzheimer's disease or a related dementia who have difficult behaviors that are upsetting for them or their caregivers. Prazosin is a medication that is commonly used to treat people with high blood pressure. Research with prazosin has shown that it may be eff...
What is the current status of trial NCT01126099?
This trial is currently completed. It is a NA study. The enrollment target is 20 participants. The study started on 2010-03. Estimated completion is 2014-03.
What interventions are being tested in trial NCT01126099?
The interventions under investigation include: Placebo (DRUG), Prazosin (DRUG).
Who is sponsoring clinical trial NCT01126099?
This trial is sponsored by Seattle Institute for Biomedical and Clinical Research, which has 43 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.